Pharmacodynamics of chloral hydrate in former preterm infants

Karel Allegaert1, Hans Daniels, Gunnar Naulaers

  • 1Neonatal Intensive Care Unit, Department of Paediatrics, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. karel.allegaert@uz.kuleuven.ac.be

Insights

Chloral hydrate sedation in former preterm infants increased bradycardic events and decreased feeding. This highlights population-specific pharmacodynamics and kinetics requiring careful consideration in neonates.

Area of Science:

  • Neonatal pharmacology
  • Pediatric sedation

Background:

  • Former preterm infants require procedural sedation.
  • Chloral hydrate is commonly used for sedation in neonates.
  • Limited data exists on chloral hydrate pharmacodynamics in this population.

Purpose of the Study:

  • To evaluate the pharmacodynamics of chloral hydrate in former preterm infants.
  • To assess sedation, feeding, and cardiorespiratory events post-administration.
  • To identify potential risks associated with chloral hydrate use in this cohort.

Main Methods:

  • Prospective evaluation of 26 former preterm infants at term post-conception age.
  • Administration of oral chloral hydrate (30 mg/kg) for procedural sedation.
  • Monitoring of COMFORT sedation scale, feeding behavior, and cardiorespiratory events (bradycardia, apneas).
  • Statistical analysis using paired Wilcoxon, McNemar, Mann Whitney U, and Fischer's exact tests.

Main Results:

  • Significant increase in sedation (decrease in COMFORT scale) up to 12 hours.
  • Minor but significant decrease in oral intake (161 to 156 ml/kg/day).
  • Significant increase in bradycardic events (e.g., <60/min: 15 to 45 events) and their duration.
  • Infants with severe bradycardia had lower gestational age at birth.

Conclusions:

  • Chloral hydrate administration was associated with increased unintended side-effects in former preterm infants.
  • Findings suggest population-specific pharmacodynamics and kinetics of chloral hydrate in this group.
  • Further inclusion was stopped due to observed adverse events.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...